Stock Markets July 9, 2026 06:57 AM

Kepler Commences Coverage of Elementis with Buy Rating, Cites Transformation as Re-rating Trigger

Broker sets 205p target as portfolio simplification and buyback signal a move toward specialty-chemical valuation

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
ELM

Kepler Cheuvreux has begun coverage of Elementis with a "buy" recommendation and a 205 pence target, pointing to a roughly 30.6% upside from the current 157 pence share price. The broker argues the market has yet to fully value Elementis's recent strategic shifts and improved operational metrics. Upcoming first-half results on July 30 are cited as the next potential catalyst for a re-rating, following a disposal of a pharmaceuticals unit and the launch of a share repurchase programme.

Kepler Commences Coverage of Elementis with Buy Rating, Cites Transformation as Re-rating Trigger
ELM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kepler Cheuvreux initiated coverage of Elementis with a "buy" rating and a target price of 205 pence, implying about 30.6% upside from a share price of 157 pence.
  • The broker argues the market is not fully valuing Elementis's transformation - operational metrics now resemble top specialty chemicals peers, including a ROCE of circa 30%.
  • Recent corporate actions include the June 2 sale of its pharmaceutical manufacturing business for an enterprise value of 34.3 million (net cash proceeds ~30 million) and a June 3 share buyback programme of up to approximately a325 million, managed by Rothschild & Co.

Kepler Cheuvreux has initiated coverage of London-listed Elementis with a "buy" rating and a target price of 205 pence, which represents an implied upside of 30.6% from the current quoted level of 157 pence.

In its initiation note, the broker said the market still appears to underweight the changes the group has made recently. Kepler highlighted that, despite trading in line with generalist chemical peers, Elementis now posts operational metrics that more closely resemble top-tier specialty chemicals companies - including a return on capital employed (ROCE) of around 30%.

Kepler added that additional proof of the company's strategic shift - manifested as robust financial results - should prompt a re-rating of the stock. The broker identified Elementis's forthcoming first-half results, scheduled for release on July 30, as the next near-term catalyst that could confirm the firm's transformation to investors.

The initiation follows two notable portfolio and capital-allocation moves by Elementis. On June 2 the company completed the sale of its pharmaceutical manufacturing business to Associated British Foods at an enterprise value of €34.3 million, generating net cash proceeds of approximately €30 million. Elementis described the transaction as one that "further strengthens the quality of our portfolio and sharpens our focus on our core markets," and said the deal repositions the group as a pure-play specialty chemicals company.

One day later, on June 3, the board announced a share buyback programme to acquire up to roughly a325 million of ordinary shares through to February 28, 2027. Rothschild & Co Global Markets Solutions Limited was appointed to manage the programme, which the company frames as an action to reduce share capital.

The combination of portfolio simplification, cash generation from the disposal and the announced buyback are the factors Kepler points to in arguing for a valuation gap versus specialty peers. The broker's view is that demonstrable delivery in upcoming reported results would be the likely trigger for market recognition of that improved positioning.


Context and next steps

Investors will be watching the July 30 first-half results for confirmation that the structural changes and capital returns are translating into the financial performance Kepler expects. Until then, the broker's initiation establishes a target and a rationale rather than presenting new operational data beyond what Elementis has already announced.

Risks

  • Upcoming first-half results on July 30 are cited as the next catalyst; if results do not confirm the transformation, the expected re-rating may not occur - this impacts equity valuations in the chemicals sector.
  • Market perception may continue to treat Elementis as a generalist chemical company despite portfolio changes, limiting near-term share-price upside - this affects investor demand for specialty-chemical exposures.
  • Execution risk around capital allocation and the buyback programme - if buyback implementation or portfolio repositioning falls short of expectations, the anticipated improvement in shareholder returns could be muted.

More from Stock Markets

B Capital and CalPERS Lead $2.8 Billion Takeover of Russell Investments Jul 9, 2026 Citi Reaffirms Select Bullish Calls in European Software While Keeping Cautious View on Sector Jul 9, 2026 Enovix Names Ex-Apple Operations Executive as COO; Shares Jump in Pre-Market Jul 9, 2026 Germany to Acquire U.S. Tomahawk Missiles and Host Them Domestically Jul 9, 2026 Virax Biolabs Shares Double After Exclusive Supply Pact with Fosun Diagnostics Jul 9, 2026